Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer

Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer

Genomic classifiers such as the Genomic Prostate Score (GPS) could help to personalize treatment for men with intermediate-risk prostate cancer (I-PCa). In this study, we aimed to evaluate the ability of the GPS to change therapeutic decision making in I-PCa. Only patients in the intermediate NCCN r...

Full description

Bibliographic Details
Main Authors: Yazid Belkacemi, Kamel Debbi, Gabriele Coraggio, Jérome Bendavid, Maya Nourieh, Nhu Hanh To, Mohamed Aziz Cherif, Carolina Saldana, Alexandre Ingels, Alexandre De La Taille, Gokoulakrichenane Loganadane
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
prostate cancer
gleason score
radiation therapy
genomic prostate score
risk assessment
Online Access:https://www.mdpi.com/2072-6694/15/3/945

Similar Items

Similar Items